UPDATE 2-Crucell wins UNICEF vaccine order after rival's recall

* $110 million order to supply UNICEF childhood vaccines

* Shantha Biotechnics aims to resume supply by end-2010

* UNICEF to review future needs mid-year

* Crucell shares up 1.4 percent

(Adds analyst and UNICEF comment, updates shares)

By Aaron Gray-Block

AMSTERDAM, May 6 (Reuters) - Dutch biotech company Crucell CRCL.AS won a $110 million order from UNICEF for paediatric vaccines, an order likely to relieve market fears about the product's growth potential.

Emerging competition from Indian rivals Panacea Biotech (PNCA.BO) and Sanofi-Aventis's (SASY.PA) Shantha Biotechnics had started to dent the growth potential for Crucell's Quinvaxem, a mix of vaccines treating five childhood diseases.

But the World Health Organisation and UNICEF said last week it was recommending the recall and destruction of Shantha's pentavalent vaccines remaining in stock due to white sediment sticking to vaccine vials. It said there have been no reports of any side effects from the use of the vaccine Shan5.

A Crucell spokeswoman said on Thursday its Quinvaxem order from UNICEF was due to supply problems experienced by another company, but declined to provide further detail.

Crucell shares were up 1.4 percent to 15.6450 euros at 1410 GMT, with the midcap index .AMX up 0.8 percent.

Crucell said the order from UNICEF to supply Quinvaxem to the developing world brought the overall value of tenders awarded to the company for 2010-2012 to $410 million.

Rabo Securities analyst Fabian Smeets said he had increased his 2010 earnings per share estimate for Crucell to 0.66 euro from 0.57, based on the increased sales.

A Shantha Biotechnics spokesman said the firm had put together a team of specialists to find the cause of the sediment in a bid to resume shipments before the end of the year.

UNICEF spokeswoman Joan Howe said a review of additional vaccine needs for 2010 and a first assessment of 2011 needs was planned around mid-year to allow for a six-month lead time.

She said Shantha has two months to get a plan in place to retain its status as World Health Organisation vaccine supplier.

Any shortfall in supplies created by the recall of affected vaccines has been fully covered by supplies UNICEF has secured via other manufacturers, Howe said. (Reporting by Aaron Gray-Block; Editing by Hans Peters and Dan Lalor)